Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine TumorGiuseppe Lamberti, Davide Campana, Antongiulio Faggiano et al.|The Journal of Clinical Endocrinology & Metabolism|2019Cited by 41
On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective StudyElena Bolzacchini, Francesco Dentali, Marco Bregni et al.|Clinical Genitourinary Cancer|2019Cited by 7
Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinibElena Bolzacchini, Francesco Dentali, Monica Giordano et al.|Tumori Journal|2021Cited by 6
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left-sided RAS/BRAF wild-type metastatic colorectal cancer: the IMPROVE-2 trialAntonio Avallone, Umberto Malapelle, Alfonso De Stefano et al.|Research Square|2025Cited by 0